Biomarkers: Next generation CNS and biofluid markers

Accelerate the development of the next generation CNS imaging ligands and biofluid molecular signatures targeting a variety of disease processes (neuroinflammation, bioenergetic/metabolic compromise, oxidative stress, synaptic pathology) that can be used as research tools or developed into diagnostic, prognostic, theragnostic or target engagement biomarkers.

2030 PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting Progression (R01) RFA-AG-15-010: Interdisciplinary Research to Understand the Vascular Contributions to Alzheimer's Disease (R01) PAR-16-266: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01) PAR-18-596: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01) NOT-AG-18-001 (#3): in vivo Synaptic Function in Alzheimer's Disease and Related Dementias RFA-AG-17-054: Enhancing the Target and Biomarker Discovery Efforts of the AMP AD and M2OVE-AD Consortia (R01) PAR-20-037: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed) PAR-20-037: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed) PAR-20-038: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) NOT-AG-22-032: Development of Radiotracers for Diagnosis and Clinical Studies in Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) PAR-25-036: Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional) 9.B In Progress Accelerate the development of the next generation CNS imaging ligands and biofluid molecular signatures... DN 2012 AD Summit: 1E 2018 AD Summit: 3O News: Decoding the molecular ties between vascular disease and Alzheimer’s News: Study links Alzheimer's disease with circular RNA News: Imaging of brain synapses could be novel test for Alzheimer's News: Large-scale analysis links glucose metabolism proteins in the brain to Alzheimer’s disease biology Molecular Mechanisms of the Vascular Etiology of Alzheimer's Disease (M²OVE-AD) Consortium Quantification of Neuroinflammation in Alzheimer's Disease Using Diffusion Basis Spectrum Imaging Imaging Oxidative Stress in an Animal Model of AD with PET Neuro-PET Radiotracer Discovery for Imaging Glycogen Synthase Kinase-3 Longitudinal Molecular Imaging of Neuropathology and Serotonin in Mild Cognitive Impairment Select projects funded in FY21 [18F]-PU-AD epichaperome PET imaging probe Sigma-1 Receptor Radioligand for Translational Research in Alzheimer's Disease Exploratory evaluation of [11C]MPC6827 Exploring the Utility of [18F]3F4AP for Demyelination Imaging in Controls, Neurodegeneration and Traumatic Brian Injury First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia Synthesized NLRP3 PET radiotracers to probe neuroinflammation in AD mice 2014

• Initiate synthesis and testing of CNS imaging ligands (PET/SPECT) for at least 12 novel, prioritized candidate targets. Ensure that these reagents are made available as open source tools for target validation and predictive drug development.
• Identify at least 6 multi-omic biomarker signatures (metabolomic, proteomic, cell-free RNAseq etc.) that can be quantitatively measured in peripheral fluids and have been validated across at least 3 diverse cohorts.